---
title: "Sotac Pharmaceuticals Ltd (SOTAC) — Share Price, Financials & Analysis"
symbol: "SOTAC"
company: "Sotac Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/SOTAC"
isin: "INE0O2D01012"
nse_symbol: "SOTAC"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 99.51
generated_at: "2026-09-13T18:45:20.227Z"
---

# Sotac Pharmaceuticals Ltd (SOTAC)

Canonical page: https://tapetide.com/stocks/SOTAC

## Company

- **NSE Symbol:** SOTAC
- **ISIN:** INE0O2D01012
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2023-04-13
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** sotacpharma.com

## About

Incorporated in 2015, Sotac Pharmaceuticals 
 Ltd manufactures and sells a wide range of pharmaceutical products[1]

## Latest Price

- **Price:** ₹90.05
- **Change:** +2.65 (+3.03%)
- **Open:** ₹90.05
- **Day High:** ₹90.05
- **Day Low:** ₹90.05
- **Previous Close:** ₹87.4
- **Volume:** 1200
- **As Of:** 2026-08-20T05:43:24+00:00

## Key Fundamentals

Observed at 2026-09-11T04:40:36.706959Z.

- **Market Cap:** ₹99.51 Cr
- **Classification:** SME
- **P/E (reported):** 17.3
- **Book Value:** ₹53.28
- **Price to Book:** 1.69
- **Dividend Yield:** 0.11%
- **ROE:** 15.88%
- **ROCE:** 18.82%
- **Debt to Equity:** 0.64
- **Revenue (yearly):** ₹101.24 Cr
- **Net Income:** ₹6.62 Cr
- **EBITDA:** ₹17.88 Cr
- **52-Week High:** ₹139.65
- **52-Week Low:** ₹86
- **RSI (14):** 31.1

## Key Insights

### Strengths

- Company has delivered good profit growth of 34.7% CAGR over last 5 years

### Weaknesses

- Company has a low return on equity of 13.0% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 73.07% | -153.19% | — |
| ebitda margin growth | 4% | 1.27% | 103.94% | 451.72% |
| net income growth | -66.67% | -28.82% | 31% | 35% |
| revenue growth | 9.02% | 0.34% | 10% | 16% |
| roce | 5.81% | 104.57% | -11.27% | 9.36% |
| roe | -68.49% | 118.73% | 11.58% | 753.76% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 40 | 38 | 52 | 52 | 53 | 47 | 37 | 60 |
| Expenses | 36 | 34 | 47 | 48 | 48 | 35 | 33 | 50 |
| Operating Profit | 3 | 4 | 4 | 4 | 4 | 12 | 4 | 10 |
| OPM % | 9 | 10 | 9 | 8 | 8 | 26 | 10 | 17 |
| Other Income | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 |
| Profit before tax | 2 | 2 | 2 | 2 | 3 | 9 | 3 | 5 |
| Tax % | 49 | 34 | 45 | -34 | 30 | 13 | 23 | 31 |
| Net Profit | 2 | 1 | 2 | 3 | 2 | 6 | 2 | 3 |
| EPS in Rs | 6.78 | 1.64 | 1.57 | 2.31 | 1.73 | 5.53 | 2.22 | 3 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 29 | 49 | 77 | 104 | 97 | 101 |
| Expenses | 27 | 47 | 70 | 95 | 83 | 83 |
| Operating Profit | 2 | 1 | 7 | 9 | 14 | 18 |
| OPM % | 7 | 3 | 10 | 8 | 14 | 18 |
| Other Income | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 0 | 1 | 2 | 2 | 3 | 4 |
| Depreciation | 1 | 3 | 2 | 3 | 4 | 5 |
| Profit before tax | 0 | -2 | 4 | 4 | 11 | 9 |
| Tax % | 75 | 15 | 42 | 10 | 17 | 28 |
| Net Profit | 0 | -2 | 2 | 4 | 9 | 6 |
| EPS in Rs | 0.39 | -10.3 | 3.58 | 3.87 | 7.27 | 5.22 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 4 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 2 | 2 | 8 | 11 | 11 | 11 |
| Reserves | 1 | 0 | 11 | 34 | 42 | 48 |
| Borrowings | 13 | 17 | 22 | 25 | 44 | 38 |
| Other Liabilities | 14 | 15 | 32 | 35 | 27 | 37 |
| Total Liabilities | 30 | 35 | 74 | 105 | 124 | 133 |
| Fixed Assets | 16 | 17 | 26 | 36 | 49 | 50 |
| CWIP | 0 | 0 | 0 | 5 | 0 | 2 |
| Investments | 0 | 0 | 0 | 2 | 4 | 3 |
| Other Assets | 14 | 18 | 48 | 63 | 72 | 79 |
| Total Assets | 30 | 35 | 74 | 105 | 124 | 133 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 0 | 8 | -16 | -4 | 17 |
| Cash from Investing Activity | -12 | -3 | -12 | -20 | -14 | -7 |
| Cash from Financing Activity | 11 | 3 | 13 | 29 | 16 | -10 |
| Net Cash Flow | 0 | 0 | 10 | -6 | -2 | 0 |
| Free Cash Flow | -10 | -3 | 0 | -34 | -16 | 9 |
| CFO/OP | 17 | 8 | 134 | -168 | -26 | 106 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 89 | 44 | 70 | 92 | 128 | 119 |
| Inventory Days | 40 | 45 | 87 | 83 | 108 | 153 |
| Days Payable | 194 | 121 | 162 | 132 | 101 | 154 |
| Cash Conversion Cycle | -66 | -32 | -5 | 43 | 136 | 118 |
| Working Capital Days | -79 | -44 | -40 | 47 | 63 | 65 |
| ROCE % | — | -5 | — | 10 | 15 | 13 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Promoters | 72.85% | 72.85% | 72.85% | 72.85% | 72.85% | 72.85% |
| FIIs | 8.51% | 8.99% | 8.88% | 15.12% | 16.14% | 16.79% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 5.32% | 5.82% | 6.01% | 4.7% | 5.13% | 6.52% |
| Others | 13.32% | 12.34% | 12.26% | 7.33% | 5.88% | 3.84% |
| No. of Shareholders | 255 | 245 | 251 | 243 | 240 | 221 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 2 / 5 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 96.24 | Sell |
| EMA (10) | 95.34 | Sell |
| SMA (20) | 102.32 | Sell |
| EMA (20) | 99.88 | Sell |
| SMA (50) | 108.14 | Sell |
| EMA (50) | 106.68 | Sell |
| SMA (100) | 115.24 | Sell |
| EMA (100) | 112.38 | Sell |
| SMA (200) | 118.12 | Sell |
| EMA (200) | 117.73 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 30.55 | Neutral |
| MACD (12,26,9) | -5.17 | Sell |
| Stochastic (14,3,3) | 15.11 | Buy |
| ADX (14) | 10.1 | Neutral |
| Williams %R (14) | -83.8 | Buy |
| ATR (14) | 3.25 | High Volatility |
| ROC (12) | -18.87 | Sell |
| Stoch RSI (14) | 22.36 | Neutral |
| UO (7,14,28) | 31.22 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Jul - Filed Regulation 74(5) certificate for quarter ended June 30, 2026; no dematerialization or rematerialization received. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 9 Jul - Filed Regulation 74(5) certificate for quarter ended June 30, 2026; no dematerialization or rematerialization received.](https://nsearchives.nseindia.com/corporate/SOTAC_09072026175707_CoveringREG_74_SIGN.pdf) |
| 9 December 2025 - Cadila order Rs.1,73,55,534 for Levozet M tablets; delivery Jan 18–30, 2026. | [Bagging/Receiving of orders/contracts 9 December 2025 - Cadila order Rs.1,73,55,534 for Levozet M tablets; delivery Jan 18–30, 2026.](https://nsearchives.nseindia.com/corporate/SOTAC_09122025150410_Regulation30.pdf) |
| 8 Sep - AGM on September 30, 2026; record date September 23, 2026 for Rs 0.20 final dividend. | [Record Date 8 Sep - AGM on September 30, 2026; record date September 23, 2026 for Rs 0.20 final dividend.](https://nsearchives.nseindia.com/corporate/SOTAC_08092026183257_Dividend_Signed.pdf) |
| 8 Sep - 11th AGM on September 30, 2026; annual report link and e-voting schedule shared. | [General Updates 8 Sep - 11th AGM on September 30, 2026; annual report link and e-voting schedule shared.](https://nsearchives.nseindia.com/corporate/SOTAC_08092026191859_Letter_of_Weblink_Sotac_Signed.pdf) |
| 8 Sep - 11th AGM on Sept 30, 2026; proposes ₹0.20 dividend and ₹85 crore related party transactions. | [Shareholders meeting 8 Sep - 11th AGM on Sept 30, 2026; proposes ₹0.20 dividend and ₹85 crore related party transactions.](https://nsearchives.nseindia.com/corporate/SOTAC_08092026182309_Notice_Signed.pdf) |
| 8 Sep - 11th AGM notice published; AGM on September 30, 2026, with annual report and e-voting details. | [Copy of Newspaper Publication 8 Sep - 11th AGM notice published; AGM on September 30, 2026, with annual report and e-voting details.](https://nsearchives.nseindia.com/corporate/SOTAC_08092026192025_Newspaper_covering_Signed.pdf) |
| 8 April 2026 - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026; no demat/remat requests received. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 8 April 2026 - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026; no demat/remat requests received.](https://nsearchives.nseindia.com/corporate/SOTAC_08042026145755_Regulation_74_5__Sign.pdf) |
| 7 Sep - Board fixed September 23, 2026 record date for Rs.0.20 dividend and called AGM on September 30, 2026. | [Appointment 7 Sep - Board fixed September 23, 2026 record date for Rs.0.20 dividend and called AGM on September 30, 2026.](https://nsearchives.nseindia.com/corporate/SOTAC_07092026185422_OutcomeSD.pdf) |
| 7 Sep - Board approved AGM on Sept 30, 2026, Rs.0.20 dividend record date Sept 23, and cost auditor appointment. | [Outcome of Board Meeting 7 Sep - Board approved AGM on Sept 30, 2026, Rs.0.20 dividend record date Sept 23, and cost auditor appointment.](https://nsearchives.nseindia.com/corporate/SOTAC_07092026184727_OutcomeSD.pdf) |
| 7 January 2026 - Sotac: Reg 27(2) corporate-governance report not applicable for quarter ended Dec 31, 2025 due to SME Emerge listing. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 7 January 2026 - Sotac: Reg 27(2) corporate-governance report not applicable for quarter ended Dec 31, 2025 due to SME Emerge listing.](https://nsearchives.nseindia.com/corporate/SOTAC_07012026123742_Regulation_27_SOTAC_Signed__1_.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31905_SOTAC_2025_2026_A_19229448_08092026182911.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28666_SOTAC_2024_2025_A_3941548_05092025194702.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25265_SOTAC_2023_2024_29082024143046.pdf) |
| from nse | [Annual Report 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_22828_SOTAC_2022_2023_19082023170931_08192023180001.zip) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:45:20.227Z.